New strategic plan (2027-2029)  with CMD is encouraging  but a game changer.

Another late-stage clinical trial setback for AstraZeneca.

Average H1 26 results, Belron strategic review (IPO) and new CEO.

Strong Q2 (May-July) and encouraging trading statement for August.

Another setback in R&D could change the market's perception on Novartis.

Feud at the top continues.